Method of use of bicycloheptane substituted prostaglandin analogs as cardiovascular agents
AssigneeE. R. Squibb & Sons, Inc.
InventorsPeter W. Sprague, Melanie J. Loots, Martin F. Haslanger
Life of this patent
Estimating the term…
Abstract
Bicycloheptane substituted prostaglandin analogs are provided having the structural formula ##STR1## and including all stereoisomers thereof. The compounds are cardiovascular agents useful, for example, in the treatment of thrombolytic disease.
Claims11
A method of inhibiting arachidonic acid-induced platelet aggregation and bronchoconstriction, which comprises administering to the circulatory system of a mammalian host an effective amount of a compound having the structural formula ##STR13## and including all stereoisomers thereof;
- wherein A is --CH.sub.2 --CH.sub.2 or --CH.dbd.CH--;
- m is 0 to 5;
- B is --CH.dbd.CH-- or (CH.sub.2).sub.2 ;
- R is H, lower alkyl, alkali metal or tris(hydroxymethyl)aminomethane;
- and R.sup.1 is aralkyl, cycloalkyl or cycloalkylalkyl or a pharmaceutically acceptable salt thereof.
A method of inhibiting bronchoconstriction associated with asthma, which comprises administering to a mammalian host an effective amount of a compound having the structural formula ##STR14## and including all stereoisomers thereof;
- wherein A is --CH.sub.2 --CH.sub.2 or --CH.dbd.CH--;
- m is 0 to 5;
- B is --CH.dbd.CH-- or (CH.sub.2).sub.2 ;
- R is H, lower alkyl, alkali metal or tris(hydroxymethyl)aminomethane;
- and R.sup.1 is aralkyl, cycloalkyl or cycloalkylalkyl or a pharmaceutically acceptable salt thereof.
A method for treating peripheral vascular disease, which comprises topically or systemically administering to a mammalian host an effective amount of a compound having the structural formula ##STR15## and including all stereoisomers thereof;
- wherein A is --CH.sub.2 --CH.sub.2 or --CH.dbd.CH--;
- m is 0 to 5;
- B is --CH.dbd.CH-- or (CH.sub.2).sub.2 ;
- R is H, lower alkyl, alkali metal or tris(hydroxymethyl)aminomethane;
- and R.sup.1 is aralkyl, cycloalkyl or cycloalkylalkyl or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.